314 related articles for article (PubMed ID: 9328363)
41. Impact of recombinant human erythropoietin treatment on left ventricular hypertrophy and cardiac function in dialysis patients.
Massimetti C; Pontillo D; Feriozzi S; Costantini S; Capezzuto A; Ancarani E
Blood Purif; 1998; 16(6):317-24. PubMed ID: 10343078
[TBL] [Abstract][Full Text] [Related]
42. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
43. Protocolized anemia management with erythropoietin in hemodialysis patients: a randomized controlled trial.
Brimble KS; Rabbat CG; McKenna P; Lambert K; Carlisle EJ
J Am Soc Nephrol; 2003 Oct; 14(10):2654-61. PubMed ID: 14514745
[TBL] [Abstract][Full Text] [Related]
44. The beneficial effect of low initial dose and gradual increase of erythropoietin treatment in hemodialysis patients.
Walter J; Gål J; Taraba I
Artif Organs; 1995 Jan; 19(1):76-80. PubMed ID: 7741644
[TBL] [Abstract][Full Text] [Related]
45. High-calorie supplementation increases serum leptin levels and improves response to rHuEPO in long-term hemodialysis patients.
Hung SC; Tung TY; Yang CS; Tarng DC
Am J Kidney Dis; 2005 Jun; 45(6):1073-83. PubMed ID: 15957137
[TBL] [Abstract][Full Text] [Related]
46. Therapy of renal anemia in children and adolescents with recombinant human erythropoietin (rHuEPO).
Campos A; Garin EH
Clin Pediatr (Phila); 1992 Feb; 31(2):94-9. PubMed ID: 1544282
[TBL] [Abstract][Full Text] [Related]
47. [Treatment of anemia in patients with chronic renal insufficiency undergoing hemodialysis with recombinant human erythropoietin: 12 months' experience].
de Sousa FT; Prata MM; Barbas JV; dos Santos JP
Acta Med Port; 1990; 3(6):347-52. PubMed ID: 2089856
[TBL] [Abstract][Full Text] [Related]
48. Use of subcutaneous recombinant human erythropoietin in children undergoing continuous cycling peritoneal dialysis.
Sinai-Trieman L; Salusky IB; Fine RN
J Pediatr; 1989 Apr; 114(4 Pt 1):550-4. PubMed ID: 2926567
[TBL] [Abstract][Full Text] [Related]
49. [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].
Kessler M; Hannedouche T; Fitte H; Cayotte JL; Urena P; Réglier JC;
Nephrol Ther; 2006 Sep; 2(4):191-9. PubMed ID: 16966064
[TBL] [Abstract][Full Text] [Related]
50. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies.
Henry DH; Abels RI
Semin Oncol; 1994 Apr; 21(2 Suppl 3):21-8. PubMed ID: 8202722
[TBL] [Abstract][Full Text] [Related]
51. [Efficacy and safety of long-term erythropoietin therapy in chronic hemodialysis patients with renal anemia].
Ohkubo M; Ishimitsu T; Kawaguchi T; Abe M; Yagi S
Nihon Jinzo Gakkai Shi; 1993 Feb; 35(2):171-7. PubMed ID: 8315880
[TBL] [Abstract][Full Text] [Related]
52. Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis.
Acharya VN; Sinha DK; Almeida AF; Pathare AV
J Assoc Physicians India; 1995 Aug; 43(8):539-42. PubMed ID: 8772973
[TBL] [Abstract][Full Text] [Related]
53. A comparison between epoetin omega and epoetin alfa in the correction of anemia in hemodialysis patients: a prospective, controlled crossover study.
Bren A; Kandus A; Varl J; Buturović J; Ponikvar R; Kveder R; Primozic S; Ivanovich P
Artif Organs; 2002 Feb; 26(2):91-7. PubMed ID: 11879235
[TBL] [Abstract][Full Text] [Related]
54. Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990-1996.
Cotter DJ; Thamer M; Kimmel PL; Sadler JH
Kidney Int; 1998 Dec; 54(6):2129-39. PubMed ID: 9853279
[TBL] [Abstract][Full Text] [Related]
55. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
Provenzano R; Bhaduri S; Singh AK;
Clin Nephrol; 2005 Aug; 64(2):113-23. PubMed ID: 16114787
[TBL] [Abstract][Full Text] [Related]
56. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
Lui SF; Law CB; Ting SM; Li P; Lai KN
Clin Nephrol; 1991 Nov; 36(5):246-51. PubMed ID: 1752075
[TBL] [Abstract][Full Text] [Related]
57. Erythropoietin hyporesponsiveness: from iron deficiency to iron overload.
Tarng DC; Huang TP; Chen TW; Yang WC
Kidney Int Suppl; 1999 Mar; 69():S107-18. PubMed ID: 10084294
[TBL] [Abstract][Full Text] [Related]
58. Endotoxin-free dialysate improves response to erythropoietin in hemodialysis patients.
Matsuhashi N; Yoshioka T
Nephron; 2002; 92(3):601-4. PubMed ID: 12372943
[TBL] [Abstract][Full Text] [Related]
59. The effect of insurance status on use of recombinant erythropoietin therapy among end-stage renal disease patients in three states.
Thamer M; Richard C; Ray NF; Greer JW; Cotter DJ; Pearson BC
Am J Kidney Dis; 1996 Aug; 28(2):235-49. PubMed ID: 8768919
[TBL] [Abstract][Full Text] [Related]
60. Anemia of chronic renal failure: treatment with erythropoietin.
Navarro M; Alonso A; Avilla JM; Espinosa L
Child Nephrol Urol; 1991; 11(3):146-51. PubMed ID: 1777893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
